Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsSubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsCharacterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell deathThr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancerCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsEvolving Therapies and FAK Inhibitors for the Treatment of CancerInhibition of CDK9 as a therapeutic strategy for inflammatory arthritis.Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.8-Amino-adenosine inhibits multiple mechanisms of transcription.3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.Novel targets for the treatment of autosomal dominant polycystic kidney disease.Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismAntitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibitionThe cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cellsThe impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease.LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patientsPharmacodynamic modelling of biomarker data in oncology.Anti-apoptotic BFL-1 is the major effector in activation-induced human mast cell survivalTargeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanismShp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.A mammalian functional-genetic approach to characterizing cancer therapeutics.Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cellsAnalogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities.Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.Roscovitine-induced apoptosis in neutrophils and neutrophil progenitors is regulated by the Bcl-2-family members Bim, Puma, Noxa and Mcl-1Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation.Efficient transient transfection of human multiple myeloma cells by electroporation--an appraisal.Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repairInsights on Structural Characteristics and Ligand Binding Mechanisms of CDK2Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
P2860
Q24561485-4937037B-D1B1-42FB-90BD-884AE49A975DQ27670943-4C514462-4C7F-4340-9D6C-544E174F5992Q27675842-1926AECE-7B2C-4896-9D92-DB5C7BF1B166Q28254233-B598A464-66ED-493D-B9F3-7CDEBACA8658Q28482928-45F3CECB-8F4E-476D-94D5-34C7DB02E020Q28484291-CE8324CC-ADEF-4859-BB94-1B6A6182C0F5Q28540339-D55BC863-FC9E-42A9-A2E1-FE986AAA335DQ28972291-5F0CE084-794D-4459-82A4-DE5790AF6D7DQ30313935-E2319D0A-0F09-4D1D-8A1C-A0A7B59A6FD8Q31160552-8526839D-95F4-412F-BE42-228AC914FB50Q33418705-79B251EC-C64F-4983-932B-92190498A1CAQ33544118-E2F15FCC-B163-410F-A17F-DDF0CC1DE71DQ33590629-253FCB96-96DD-45BE-B45E-282CFB902408Q33662495-D0B2AF8F-1529-4A02-8846-56623954338EQ33702365-DCFA913A-0FB5-44E1-B9DE-D397D2888559Q33816594-270CDEF4-F73F-4B9F-A49B-3EAD30BA36A7Q33963772-DCFFCADD-8F92-4F52-842D-58D7F4B533E5Q34079481-E10FAB39-6142-4DFA-9D92-C9AD0E2B4961Q34103117-9D3878B7-5C50-46A9-A4B3-1B8C5F5825EFQ34178106-4B2A69C5-A696-4414-AFF9-5510C93F6E93Q34195072-14BC8D9C-9133-4B01-9755-B59BD3CBB951Q34205236-21A94DDA-85A1-4B95-B795-03E9399956BBQ34220979-7DA5AF3C-4A14-4426-B892-0EABC9DD84D5Q34241935-B46B6731-2EF5-43B2-A353-66BCBE018E9BQ34312178-1C4C3719-D469-41FF-8A4F-0FD20060F23FQ34365839-C45588FA-22BB-4BB4-A2DF-A7EA91327054Q34393767-27815C0D-C248-426B-9B1F-BC9D092F497BQ34399676-4E3D0CB7-DCA3-47C5-885E-08F75CFAB133Q34760557-3452E488-6966-471E-8C34-0FCF61F5AE31Q34773140-A42F929D-3119-4786-B781-430374758ECAQ34857289-CDFE97EC-F8EE-424F-BAAC-E817E2EBC819Q35011009-73F89588-079C-4589-A452-5C678C4D52FEQ35041268-6EC27B84-D66F-4A3B-B36F-463176830028Q35125652-1CBD9864-A792-4CE7-A519-B66179F8DFA1Q35182314-B88E4C0A-3A92-4457-80CB-49BC27A4D032Q35543223-9117395E-E8CF-4093-98A9-2EF1D25EE708Q35574807-B64AF139-4142-43B4-8972-46473857C6E5Q35722786-9A5D6331-A177-49C1-8CF0-8145C2A2B715Q35882493-3F368731-62C8-4B01-AE3E-58B99AB2A605Q35920657-459E0A01-7C78-4A62-B444-612720D473BA
P2860
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@ast
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@en
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@nl
type
label
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@ast
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@en
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@nl
prefLabel
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@ast
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@en
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@nl
P2093
P3181
P1433
P1476
Seliciclib (CYC202, R-Roscovit ...... n and down-regulation of Mcl-1
@en
P2093
Athos Gianella-Borradori
David E MacCallum
Jean Melville
Kathryn Watt
Sheelagh Frame
Sian Anderson
Simon R Green
P304
P3181
P356
10.1158/0008-5472.CAN-05-0233
P407
P50
P577
2005-06-01T00:00:00Z